Methods
I. Literature search The National Library of Medicine (PubMed) was used to identify all clinical trials relating to the treatment of prostate cancer. We used the PubMed search strategy using the following search terms : prostatic neoplasms, gonadorelin, androgen antagonists, antineoplastic agents, orchiectomy, bone and bones, bone density, osteoporosis and fractures, as well as the term of clinical trials. Literature search was conducted from original articles published between the year 1966 and August 2003. The reference lists of studies included in the meta-analysis were manually collected to include any citations that were missed by the electronic searches.
Selection and data abstraction
Initially, all the randomized controlled clinical trials were selected for further assessment. We screened titles and abstracts from potentially eligible studies, and selected studies conducted on patients with prostate cancer as the subjects who were being initiated on treatment or were at the time under treatment with a gonadotropin-releasing hormone (GnRH) agonist, antiandrogen and orchiectomy. Two investigators independently assessed each article for eligibility, and any disagreement was settled by consensus. For each eligible study, we collected the information on study design, number of participants, mean age, type of prostate cancer, type of bone mineral density measurements, calcium supplement, type of androgen deprivation therapy, and the followup period. As regards to the study quality, a randomized controlled trial was rated the grade 'a' , while a single arm trial of androgen deprivation therapy only or controlled trials with unknown randomization were rated the grade 'b' although all these trials were included into the analysis.
Outcome measures
The primary outcome measure was the mean loss in bone mineral density (in grams per surface unit, or sometimes, grams per volume of a circumscribed area [content] ) that was obtained as a percentage change from the initial value.
It was recorded at the femoral neck, lumbar spine and hip for each group (androgen deprivation therapy or control). Although any assessment of bone mineral density was made at the 6 months and/or 12 months after the initiation of therapy, the data at 12 months were utilized if both data were available.
Statistical analysis
All the analyses were performed according to the intention-to-treat principle. The pooled estimate of bone mineral density percentage change was estimated by the weighted mean of bone mineral density percentage changes where the weight was set as an inverse of square of the standard deviation (SD). When the mean percentage change of bone mineral density was not reported in the article, we approximated this value by dividing the reported absolute change of bone mineral density by its baseline value. Where standard error of the mean (SEM) was reported instead of SD, SD was calculated as SEM multiplied bywhere n is the number of participants. Where no SD was reported, it was imputed by using the mean from the other trials. The effect size was defined by the mean difference of bone mineral density decrease between androgen deprivation therapy and control group during 6 or 12 months, divided by its SD. The value of effect size greater than 0 means a decreasing bone mineral density in the androgen deprivation therapy. The pooled effects size by androgen deprivation therapy in decreasing bone mineral density was estimated by using a fixed-effect model. Heterogeneity was investigated as in interaction between the study and its effect size in the above model.
Results

I. Literature search and critical appraisal
After a review of the abstracts in the search, 24 papers were found relating to androgen-deprivation-therapyassociated bone loss. Of these, we excluded 4 papers, because 2 were case reports and 2 were letters. Twenty of the 24 papers were potentially relevant, and were subjected to strict quality and eligibility assessment. Of the 20, 6 were excluded, because they lacked the bone mineral density values. A further 4 papers were excluded because the bone mineral density after 6 and 12 months of androgen deprivation therapy had not been evaluated. Ten trials fulfilled all the inclusion criteria15-24). Since one of these trials reported 2 treatment groups (orchiectomy, chemical castration), the data were regarded as 2 studies. Table 1 Table 2 , Table 3 and Table 4 show a summary of the trial results.
Meta-analysis
Changes in the bone mineral density of the femoral neck for the androgen deprivation therapy group ranged between-0.6 and 6.5 % decrease at 6 months and the weighted mean Fig. 1 . In comparison with that in the control group, the bone mineral density at all the sites examined was significantly decreased after 6 or 12 months according to the use of androgen deprivation therapy.
Discussion
Although osteoporosis has long been considered as a disease of women, in the earliest reports of the epidemiology of osteoporosis, it was apparent that the classical age-related increase in the frequency of fractures seen in women is also evident in men. In fact, by World Health Organization criteria, the prevalence rates of osteoporosis at the hip, spine or wrist after age 50 years appears to be higher in women (35 %) than in men (19%). Yet, the actual prevalence rates of osteoporotic fracture do not differ between men (10%) and women (13%)25). These indicate that men have a higher risk of fracture than women with the same degree of decrease in bone mineral density. Moreover, one-seventh of all vertebral compression fractures and one-fourth to one-fifth of all hip fractures occur in men26), and mortality related to hip fractures is higher in men than in women27). In a recent study, skeletal fractures in men with prostate cancer were negatively associated with the overall survival, independent of other prognostic factors28). Increasing duration of androgen deprivation therapy was significantly associated with increasing fracture risk in men with prostate cancer. Hip fractures are a major cause of disability and functional impairment. The results of our systematic review show that the bone mineral density (weighted mean) was decreased by 2.8 % (0.3 to 5.3%) at the femoral neck, by 2.7 % (-0.2 to 5.6%) at the lumbar spine, and by 1.5% (-0.7 to 3.7 %) at the hip after 12 months of androgen deprivation therapy. The rates of bone mineral loss about 2-3 % per year, as estimated in the present study, should not be negligible, because the bone loss continuously progresses during the chronic androgen deprivation therapy : for example, the spinal bone mineral density values were 14% less, and the hip bone mineral density values were 28 % less, than those observed in age-matched control individuals after 10 years of the therapy29). In contrast, the bone mineral density did not significantly change at any of these skeletal sites in the control group. Attention should therefore be focused on preventing osteoporosis in patients receiving androgen deprivation therapy. In normal men after the age of 55 years, the bone mineral density is reported to gradually increase via the formation of spinal osteophytes and calcification of paravertebral structures when measured by dual energy x-ray absorptiometry30). The present analysis, however, could not detect the age-related changes, probably because of the short follow-up period (6-12 months).
Androgen deprivation therapy is associated with a decrease in the levels of testosterone and dihydrotestosterone to castration levels. The hypogonadism has been reported to be a major risk factor for osteoporosis in adult men. Longstanding hypogonadism secondary to hyperprolactinemia has been shown to be associated with significant reductions in spinal and cortical bone density in men. Testosterone therapy given to adult men with acquired hypogonadism is associated with reduced bone remodeling and increase of trabecular bone density31). Thus, it was surmised that androgen deprivation therapy might cause osteoporosis. Androgens mediate osteoblast proliferation and differentiation, and increase bone matrix production and osteocalcin secretion, via the androgen receptors present on osteoblasts. Testosterone also modulates the effects of various growth factors, includ- sure was achieved after nine months34). In contrast, testosterone has been shown to have no effect on skeletal maturation. Furthermore, a 28-year-old man with a point-mutation of the estrogen receptor gene which was associated with complete estrogen resistance exhibited severe defect of skeletal growth resulting in delayed epiphyseal closure and bone age, tall stature, increased bone turnover, and severely reduced bone mineral density for his chronological age35). In fact, estrogen receptors are expressed in both osteoblasts and osteoclasts36). These indicate that estrogen plays an important role in bone maturation and mineralization as much in men as in women.
Several treatment possibilities exist for osteoporosis asso- Only the data from Diamond's study represent the change at 6 months because the data at 12 months are not available. A fixed-effect model was used to obtain a pooled effect size and 95 % confidence interval (CI). N1, number of patients in the androgen-deprivation-therapy group (ADT). N2, number of patients in the control group (CTL). Effect, effect size. Lower and Upper, lower and upper 95 % CI of effect size. NTotal, total sample size. P, statistical P value. Subtotal (Fixed Combined) values were obtained using the fixed effect model. Plot shows the meta-analytically pooled effect size (crossing point) with 95 % CI (horizontal bar) or the combined effect size associated with 95 % CI (rhombs). ciated with androgen deprivation therapy. Medical castration with estrogens is not associated with bone loss in men with prostate cancer15), although this treatment strategy has been abandoned because of the high rates of cardiovascular toxicity. Bisphosphonates may prevent or reverse some or all of the bone mineral density loss associated with androgen deprivation therapy. Smith et al. who randomized 43 men with nonlocalized or recurrent prostate cancer treated with leuprolide to receive intravenous pamidronate, found no change of the bone mineral density in the hip or the lumbar spine20). Thus, bisphosphonates may delay the progression of skeletal metastases arising from prostate cancer37).
In conclusion, this study provides new and important information on osteoporosis during androgen deprivation therapy. The hormonal therapy seems to promote bone loss via multiple mechanisms. It would thus be reasonable to measure the bone mineral density in all men prior to the commencement of androgen deprivation therapy. Calcium and vitamin D supplementation and advice for abstinence from smoking and alcohol are suitable first-line preventive measures against bone loss under this condition. Treatment with bisphosphonates may also be a possible strategy to prevent bone loss, although further research is needed to explore the effects of bisphosphonates. 
